Uses for polycationic compounds

Details Uses for polycationic compounds Uses for polycationic compounds

2007-07-17

2007-07-17

Campell, Bruce R. (Department: 1648)

Drug, bio-affecting and body treating compositions

Nonspecific immunoeffector, per se ; or nonspecific...

C424S280100, C424S282100, C424S184100, C514S001000, C514S004300, C514S04400A

Reexamination Certificate

active

10250953

ABSTRACT:
The invention relates to the use of a polycationic compound for the preparation of a medicament with retarded in vivo release.

REFERENCES:
patent: 5109026 (1992-04-01), Hoskinson et al.
patent: 6528058 (2003-03-01), Edgar et al.
patent: 6544518 (2003-04-01), Friede et al.
patent: 6589940 (2003-07-01), Raz et al.
patent: 744988 (1956-02-01), None
patent: 1290141 (1972-09-01), None
patent: 2000256196 (2000-09-01), None
patent: WO 91/04052 (1990-09-01), None
patent: WO 97/10840 (1997-03-01), None
patent: WO 97/30721 (1997-08-01), None
patent: WO 99/38528 (1999-08-01), None
patent: WO 00/00214 (2000-01-01), None
patent: WO 00/41679 (2000-07-01), None
patent: WO 00/62800 (2000-10-01), None
patent: WO 01/24822 (2001-04-01), None
patent: WO 01/34206 (2001-05-01), None
patent: WO 01/93905 (2001-06-01), None
patent: WO 01/93903 (2001-12-01), None
patent: WO 02/13857 (2002-02-01), None
patent: WO 02/32451 (2002-04-01), None
Mirchamsy et al., Biologicals, vol. 24 No. 4, pp. 343-350 (Dec. 1996).
Boucher et al. Infection and Immunity, vol. 62 No. 2, pp. 449-456 (Feb. 1994).
Marshall et al., “Superior Activity of the Type C Class of ISS In Vitro and In Vivo Across Multiple Species,” DNA and Cell Biology, vol. 24 No. 2, pp. 63-72 (2005).
Andreu and Rivas, “Animal Antimicrobial peptides: an overview,”Biopoly, 47:415-433, 1998.
Ballas et al., “Induction of nk activity in murine and human cells by cpg motifs in oligodeoxynucleotides and bacterial dna,”J. Immunology, 157:1840-1845, 1996.
Bloom and Widdus, “Vaccine visions and their global impact,”Nature Med. Vacc. Supp., 4;480484, 1998.
Buschle et al., “Development of defined synthetic vaccines by in vivo charging of antigen presenting cells with antigen,”J. Invest. Derma., 114:235, Abstract, 2000.
Buschle et al., “Transloading of tumor antigen-derived peptides into antigen-presenting cells,”Proc. Natl. Acad. Sci. USA, 94:3256-3261, 1997.
Buschle et al., “Chemically defined, cell-free cancer vaccines: use of tumor antigen-derived peptides or polyepitope proteins for vaccination,”Gene Ther. Mol. Biol., 1:309-321, 1998.
Chace et al., “Bacterial dna-induced nk cell ifn-γ production is dependent on macrophage secretion of IL-12,”Clin. Immunol. and Immunopathology, 84:185-193, 1997.
Co-pending U.S. Appl. No. 10/344,709, (SONN:030US) filed Feb. 14, 2003, by Jörg Fritz et al.
Davis et al., “CpG dna is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis b surface antigen,”J. Immunology, 160:870-876, 1998.
Deng et al., “Intra-articularly localized bacterial dna containing cpg motifs induces arthritis,”Nature Med., 5:702-705, 1999.
Gall et al., “Adjuvant activity of polyelectrolytes,”Immunology, 23:569-575, 1972.
Ganz and Lehrer, “Antibiotic peptides from higher eukaryotes: biology and applications,”Molecular Medicine Today, 5:292-297, 1999.
Ganz, “Enhanced: defensins and host defense,”Science, 286:420-421, 1999.
Hancock, “Host defence (cationic) Peptides, what is their future clinical potential?”Drugs, 57:469-473, 1999.
Hartmann et al., “CpG dna: a potent signal for growth, activation, and maturation of human dendritic cells,”Proc. Natl. Acad. Sci. USA, 96:9305-9310, 1999.
Hoffmann et al., “Phylogenetic perspectives in innate immunity,”Science, 284:1313-1317, 1999.
Immunology, Fifth Edition, Roitt, Beastoff, Nale, eds., 1998.
Klinman et al., “CpG motifs present in bacterial dna rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon γ,”Proc. Natl. Acad. Sci. USA, 93:2879-2883, 1996.
Krieg et al., “CpG motifs in bacterial dna trigger direct b-cell activation,”Nature, 374:546-549, 1995.
Krieg et al., “The role of CpG dinucleotides in dna vaccines,”Trends in Microbiology, 6:23-27, 1998.
Krieg, “An innate immune defense mechanism based on the recognition of cpg motifs in microbial dna,”J. Lab. Clin. Med., 128:128-133, 1996.
Krieg, “CpG dna: a novel immunomodulator,”Trends in Microbiology, 7:64 1999.
Lethe et al., “Mouse tumor rejection antigens P815A and P815B: two epitopes carred by a single peptide,”Eur. J. Immunol., 22:2283-2288, 1992.
Liebert, “CpG: the double-edged sword,”Human Gene Therapy, 10:2089-2090, 1999.
Liljeqvist and Stahl, “Production of recombinant subunit vaccines: protein immunogens, live delivery systems and nucleic acid vaccines,”J. Biotech., 73:1-33, 1999.
Lipford et al., “Bacterial dna as immune cell activator,”Trends in Microbiology, 6:496-500, 1998.
McCluskie et al., “Novel strategies using dna for the induction of mucosal immunity,”Critical Reviews in Immunology, 19:303-329, 1999.
Mosmann et al., “Two types of murine helper t cell clone,”J. Immunol., 136:2347-2357, 1986.
Nossal, “Living up to the legacy,”Nature Med. Vaccine Suppl., 4:475-476, 1998.
Oxenius et al., “CpG-containing oligonucleotides are efficient adjuvants for induction of protective antiviral immune responses with t-cell peptide vaccines,”J. Virology, 73:4120-4126, 1999.
Pamer et al., “Precise prediction of a dominant class I MHC-restricted epitope of listeria monocytogenes,”Nature, 353, 852-855, 1991.
Parronchi et al., “Phosphorothioate oligodeoxynucleotides promote the in vitro development of human allergen-specific CD4+ t cells into th1 effectors,”J. Immunology, 163:5946-5953, 1999.
Pisetsky, Immunostimulatory dna: a clear and present danger?Nature Medicine, 3:829-831, 1997.
Pisetsky, The Influence of base sequence on the immunostimulatory properties of dna,Immunologi Res., 19:35-46, 1999.
Rodrigues et al., “The in vivo cytotoxic activity of CD8+ t cell clones correlates with their levels of expression of adhesion molecules,”J. Exp. Med., 175:895-905, 1992.
Rotzschke et al., “Exact prediction of a natural t cell epitope,”Eur. J. Immunol., 21:2891-2984, 1991.
Schmidt et al., “Cell-free tumor antigen peptide-based cancer vaccines,”Proc. Natl. Acad. Sci. USA, 94:3262-3267, 1997.
Schwartz et al., “CpG motifs in bacterial dna cause inflammation in the lower respiratory tract,”J. Clin. Invest., 100:68-73, 1997.
Shimonkevits et al., “Antigen recognition by h-2-restricted t cells,”J. Immunol., 133: 2067-2075, 1984.
Simmaco et al., “Antimicrobial peptides from amphibian skin: what do they tell us?”Biopoly, 47:435-450, 1998.
Sparbier and Walden, “T cell receptor specificity and mimotopes,”Current Opin. Immun., 11:214-218, 1999.
Sparwasser et al., “Bacterial dna and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells,”Eur. J. Immunol., 28:2045-2054, 1998.
Sparwasser et al., “Bacterial dna causes septic shock,”Nature, 386:336-337, 1997.
Sparwasser et al., “Macrophages sense pathogens via dna motifs: induction of tumor necrosis factor-α-mediated shock,”Eur. J. Immunol., 27:1671-1679, 1997.
Weiner et al., “Immunostimulatory oligodeoxynucleotides containing the cpg motif are effective as immune adjuvants in tumor antigen immunization,”Proc. Natl. Acad. Sci. USA, 94:10833-10837, 1997.
Yew et al., “Contribution of Plasmid dna to inflammation in the lung after administration of cationic lipid:pdan complexes,”Human GeneTherapy, 10:223-234, 1999.

Affiliated with

Also associated with

Rating

Uses for polycationic compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Uses for polycationic compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Uses for polycationic compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3806326